SG10201703707YA - Pharmaceutical formulation containing improved antibody molecules - Google Patents
Pharmaceutical formulation containing improved antibody moleculesInfo
- Publication number
- SG10201703707YA SG10201703707YA SG10201703707YA SG10201703707YA SG10201703707YA SG 10201703707Y A SG10201703707Y A SG 10201703707YA SG 10201703707Y A SG10201703707Y A SG 10201703707YA SG 10201703707Y A SG10201703707Y A SG 10201703707YA SG 10201703707Y A SG10201703707Y A SG 10201703707YA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical formulation
- antibody molecules
- formulation containing
- improved antibody
- containing improved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009069095 | 2009-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201703707YA true SG10201703707YA (en) | 2017-06-29 |
Family
ID=42739479
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201900451SA SG10201900451SA (en) | 2009-03-19 | 2010-03-19 | Pharmaceutical formulation containing improved antibody molecules |
SG10201703707YA SG10201703707YA (en) | 2009-03-19 | 2010-03-19 | Pharmaceutical formulation containing improved antibody molecules |
SG2011066768A SG174428A1 (en) | 2009-03-19 | 2010-03-19 | Pharmaceutical formulation containing improved antibody molecules |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201900451SA SG10201900451SA (en) | 2009-03-19 | 2010-03-19 | Pharmaceutical formulation containing improved antibody molecules |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011066768A SG174428A1 (en) | 2009-03-19 | 2010-03-19 | Pharmaceutical formulation containing improved antibody molecules |
Country Status (8)
Country | Link |
---|---|
JP (2) | JP4885308B2 (ja) |
KR (1) | KR101468271B1 (ja) |
AR (1) | AR075908A1 (ja) |
AU (1) | AU2010225951B2 (ja) |
RU (1) | RU2565809C2 (ja) |
SG (3) | SG10201900451SA (ja) |
TW (1) | TWI440470B (ja) |
WO (1) | WO2010106812A1 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
SA111320266B1 (ar) | 2010-03-11 | 2015-06-21 | رينات نيوروساينس كوربوريشن | أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني |
CN103476793A (zh) * | 2010-11-08 | 2013-12-25 | 基因技术公司 | 皮下施用的抗-il-6受体抗体 |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
US20140080153A1 (en) * | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
BR112013021526B1 (pt) * | 2011-02-25 | 2021-09-21 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio |
WO2012132067A1 (ja) * | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
US20160340730A1 (en) * | 2013-12-20 | 2016-11-24 | Diogenix, Inc. | Methods for evaluating neurological disease |
MX2016008498A (es) | 2013-12-27 | 2016-10-07 | Chugai Pharmaceutical Co Ltd | Metodo para purificar anticuerpo que tiene bajo punto isoelectrico. |
TWI805046B (zh) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
CN107614683B (zh) | 2015-05-22 | 2020-12-22 | 安斯泰来制药株式会社 | 新型抗人NGF抗体Fab片段 |
CN108430507B (zh) | 2015-12-18 | 2022-08-02 | 安斯泰来制药株式会社 | 含有抗人tslp受体抗体的药物组合物 |
RU2019112680A (ru) * | 2016-09-27 | 2020-10-29 | Фрезениус Каби Дойчланд Гмбх | Жидкая фармацевтическая композиция |
AU2018227036B2 (en) * | 2017-03-01 | 2021-07-08 | Medimmune Limited | Formulations of monoclonal antibodies |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
JP2021504482A (ja) * | 2017-11-30 | 2021-02-15 | バイオ−テラ ソリュ−ションズ,エルティーディー. | Il‐6関連疾患を治療するためのヒト化抗体の液体製剤 |
WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Il-6阻害剤を含有する喘息の治療剤 |
CA3110891A1 (en) | 2018-08-29 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating subjects having rheumatoid arthritis |
US11498969B2 (en) | 2019-01-31 | 2022-11-15 | Sanofi Biotechnology | Compositions and methods for treating juvenile idiopathic arthritis |
US20220220210A1 (en) | 2019-03-29 | 2022-07-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function |
JP7501876B2 (ja) | 2019-04-17 | 2024-06-18 | 国立大学法人広島大学 | Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 |
EP4159236A1 (en) | 2020-05-29 | 2023-04-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
WO2022191306A1 (ja) | 2021-03-12 | 2022-09-15 | 中外製薬株式会社 | 重症筋無力症の治療または予防用の医薬組成物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ20003099A3 (cs) * | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
IL161968A0 (en) * | 2001-11-14 | 2005-11-20 | Centocor Inc | Anti-il-6 antibodies, compositions, methods and uses |
EP3192528A1 (en) * | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
SI1562972T1 (sl) * | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO |
JP4607010B2 (ja) * | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | タンパク質含有安定化製剤 |
JP4685764B2 (ja) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のFcRn結合親和力又は血清半減期の改変 |
ATE464908T1 (de) * | 2004-02-11 | 2010-05-15 | Warner Lambert Co | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US9084777B2 (en) * | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
US20080071063A1 (en) * | 2006-02-03 | 2008-03-20 | Medimmune, Inc. | Protein Formulations |
US11046784B2 (en) * | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
MX2008014804A (es) * | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
PH12018501459A1 (en) * | 2007-09-26 | 2019-11-11 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
CL2008002885A1 (es) * | 2007-09-26 | 2010-07-02 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende |
MX369784B (es) * | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
DK2708559T3 (en) * | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
-
2010
- 2010-03-19 RU RU2011142184/10A patent/RU2565809C2/ru active
- 2010-03-19 KR KR1020117024548A patent/KR101468271B1/ko active IP Right Grant
- 2010-03-19 SG SG10201900451SA patent/SG10201900451SA/en unknown
- 2010-03-19 WO PCT/JP2010/001977 patent/WO2010106812A1/en active Application Filing
- 2010-03-19 AR ARP100100904A patent/AR075908A1/es unknown
- 2010-03-19 SG SG10201703707YA patent/SG10201703707YA/en unknown
- 2010-03-19 TW TW099108118A patent/TWI440470B/zh active
- 2010-03-19 JP JP2010522524A patent/JP4885308B2/ja active Active
- 2010-03-19 SG SG2011066768A patent/SG174428A1/en unknown
- 2010-03-19 AU AU2010225951A patent/AU2010225951B2/en active Active
-
2011
- 2011-05-09 JP JP2011104179A patent/JP5661553B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR101468271B1 (ko) | 2014-12-03 |
AU2010225951B2 (en) | 2014-03-13 |
KR20110139745A (ko) | 2011-12-29 |
AR075908A1 (es) | 2011-05-04 |
JP2011173918A (ja) | 2011-09-08 |
WO2010106812A1 (en) | 2010-09-23 |
SG10201900451SA (en) | 2019-02-27 |
TW201100100A (en) | 2011-01-01 |
RU2011142184A (ru) | 2013-04-27 |
TWI440470B (zh) | 2014-06-11 |
SG174428A1 (en) | 2011-10-28 |
RU2565809C2 (ru) | 2015-10-20 |
AU2010225951A1 (en) | 2011-09-22 |
JP5661553B2 (ja) | 2015-01-28 |
JP2012504106A (ja) | 2012-02-16 |
JP4885308B2 (ja) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201703707YA (en) | Pharmaceutical formulation containing improved antibody molecules | |
HK1246170A1 (zh) | 藥物組合物 | |
ZA201006029B (en) | Pharmaceutical dosage form | |
ZA201204266B (en) | Antibody formulation | |
HK1160389A1 (en) | Stable liquid antibody formulation | |
ZA201106503B (en) | Antibody formulation | |
ZA201203242B (en) | Antibody formulation | |
IL225457A0 (en) | Pharmaceutical composition | |
HK1169960A1 (en) | Pharmaceutical formulation | |
GB0810615D0 (en) | Novel pharmaceutical | |
ZA201104348B (en) | Pharmaceutical preparation | |
EP2484697A4 (en) | ANTIPODOPLANIN ANTIBODY AND PHARMACEUTICAL COMPOSITION CONTAINING ANTIPODOPLANIN ANTIBODY | |
ZA200903858B (en) | Pharmaceutical dosage form | |
PL394605A1 (pl) | Trwała złożona kompozycja farmaceutyczna | |
GB201010453D0 (en) | Pharmaceutical composition | |
GB0815972D0 (en) | Pharmaceutical preparation | |
ZA201207375B (en) | Stabilized pharmaceutical composition | |
EP2306998A4 (en) | PHARMACEUTICAL FORMULATION | |
GB0810617D0 (en) | Novel pharmaceutical | |
GB201001911D0 (en) | Pharmaceutical composition | |
HK1131039A1 (en) | Pharmaceutical use of sophoricoside | |
HK1182939A1 (en) | Stable pharmaceutical composition | |
GB0805292D0 (en) | Pharmaceutical formulation | |
GB0804486D0 (en) | Novel pharmaceutical composituons | |
GB201019775D0 (en) | Pharmaceutical composition |